Fresenius Medical Care AG & Co. (FMS) to Release Quarterly Earnings on Tuesday

Fresenius Medical Care AG & Co. (NYSE:FMS) will be posting its quarterly earnings results before the market opens on Tuesday, October 30th. Analysts expect Fresenius Medical Care AG & Co. to post earnings of $0.67 per share for the quarter.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings results on Tuesday, July 31st. The company reported $0.54 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.06). The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.28 billion. Fresenius Medical Care AG & Co. had a return on equity of 10.78% and a net margin of 11.65%. The business’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.89 earnings per share. On average, analysts expect Fresenius Medical Care AG & Co. to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Fresenius Medical Care AG & Co. stock opened at $40.06 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.37 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $24.55 billion, a price-to-earnings ratio of 18.13, a price-to-earnings-growth ratio of 1.90 and a beta of 0.80. Fresenius Medical Care AG & Co. has a twelve month low of $38.91 and a twelve month high of $57.94.



Several analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “sell” rating in a research note on Friday, August 3rd. Royal Bank of Canada reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research note on Friday, August 17th. ValuEngine downgraded shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. Bank of America assumed coverage on shares of Fresenius Medical Care AG & Co. in a research note on Monday, July 9th. They issued a “buy” rating for the company. Finally, HSBC raised shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “buy” rating in a research note on Tuesday, August 28th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $67.33.

An institutional investor recently raised its position in Fresenius Medical Care AG & Co. stock. Bank of New York Mellon Corp grew its position in shares of Fresenius Medical Care AG & Co. (NYSE:FMS) by 6.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,061 shares of the company’s stock after acquiring an additional 1,731 shares during the period. Bank of New York Mellon Corp’s holdings in Fresenius Medical Care AG & Co. were worth $1,463,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.46% of the company’s stock.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA provides products and services for patients with chronic kidney failure. The company’s products include dialysis machines, dialyzers and related disposables. It also offers renal information technology solutions and provides services such as renal replacement therapy and therapeutic apheresis.

Featured Article: How to Invest in the Dividend Aristocrat Index

Earnings History for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply